Loading…

A087: Moxonidine and amlodipine effects on lipid profile, urinary sodium excretion and caloric intake in obese hypertensive patients

The present study has been conducted to evaluate the chronic effects (7 months) of Moxonidine (M) and Amlodipine (A) on lipid profile and urinary sodium excretion in patients with Metabolic Syndrome. Twenty seven obese hipertensive subjects (BMI = 33 ± 1.0, MBP = 124.6 ± 1.6 mmHg, 4 males, 23 female...

Full description

Saved in:
Bibliographic Details
Published in:American journal of hypertension 2000-04, Vol.13 (S2), p.144A-144A
Main Authors: Sanjuliani, A.F., Barroso, S.G., Fagundes, V.G.A., Rodrigues, M.L.G., Moulin, C.S., Netto, J.F., Francischetti, E.A.
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 144A
container_issue S2
container_start_page 144A
container_title American journal of hypertension
container_volume 13
creator Sanjuliani, A.F.
Barroso, S.G.
Fagundes, V.G.A.
Rodrigues, M.L.G.
Moulin, C.S.
Netto, J.F.
Francischetti, E.A.
description The present study has been conducted to evaluate the chronic effects (7 months) of Moxonidine (M) and Amlodipine (A) on lipid profile and urinary sodium excretion in patients with Metabolic Syndrome. Twenty seven obese hipertensive subjects (BMI = 33 ± 1.0, MBP = 124.6 ± 1.6 mmHg, 4 males, 23 females, age 49.3 ± 1.5 yrs) were randomly assigned to receive M [(n = 17), 49.3 ± 1.9 yrs] or A [(n = 10), 48.3 ± 2.4 yrs]. Both A and M caused significant reduction in systolic, diastolic and mean blood pressure (MBP), although no significant difference was observed between the two groups [MBP: M-122.8 ± 1.5 vs 111.2 ± 3.6 mmHg (p = 0.003), A-127.1 ± 2.6 vs 106.0 ± 2.4 (p = 0.0001)]. In conditions of adequate control of sodium and calories intake, the urinary excretion of sodium/creatinine in 12h (NaU) decreased in both groups during blood pressure reduction, but significantly less (p = 0.03) in the M group (21.65 ± 3.992 vs 19.22 ± 2.26 mmol/mmol) when compared to the A group (16.95 ± 2.77 vs 10.92 ± 2.77 mmol/mmol). We observed a significant diminution of energy intake (1987 ± 60, vs 1784 ± 119 calories, p < 0.05), as well as on the waist circumference in the M group (104.4 cm vs 103 cm, p < 0.04), but not in the A group (2229 ± 244 vs 1923 ± 298 calories, p = 0.19 and 100.4 vs 101 cm, p = 0.78). There was a 12% reduction of serum triglycerides concentration with M. Both drugs showed no significant effects on plasma glucose, HDL-C and LDL-C. The administration of M, when compared to A, to obese hypertensive patients reduced the intake of calories, waist circumference and serum triglycerides. Besides having the same antihypertensive efficacy, Moxonidine retained less sodium than Amlodipine.
doi_str_mv 10.1016/S0895-7061(00)00620-8
format article
fullrecord <record><control><sourceid>proquest_istex</sourceid><recordid>TN_cdi_proquest_journals_1038141855</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2753710621</sourcerecordid><originalsourceid>FETCH-LOGICAL-i665-2382f37646537013afad1c18b85664717f135eda159963f6421c3037d23b82973</originalsourceid><addsrcrecordid>eNo9j01LxDAYhIMouH78BCHgRcFq3qT5qDcRXYV1hVVQvJRs-xaj3bQmWdm9-8OtKJ6GGR5mGEIOgJ0CA3X2wEwhM80UHDF2zJjiLDMbZARFDpnmXG6S0T-yTXZifGOM5UrBiHxdMKPP6V236ryrnUdqfU3tou1q1_9YbBqsUqSdp-2Q1LQPXeNaPKHL4LwNaxoHdLmguKoCJjdwPw2VbbvgKup8su84CO3mGJG-rnsMCX10n0h7mxz6FPfIVmPbiPt_ukser68eL2-yyf349vJikjmlZMaF4Y3QKldSaAbCNraGCszcSKVyDboBIbG2IItCiUblHCrBhK65mBteaLFLDn9rhwsfS4ypfOuWwQ-LJTBhIAcj5UBlv5SLCVdlH9xieFna8F4qLbQsb55fyqnmk9l49lROxTfP7XJm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1038141855</pqid></control><display><type>article</type><title>A087: Moxonidine and amlodipine effects on lipid profile, urinary sodium excretion and caloric intake in obese hypertensive patients</title><source>Oxford Journals Online</source><creator>Sanjuliani, A.F. ; Barroso, S.G. ; Fagundes, V.G.A. ; Rodrigues, M.L.G. ; Moulin, C.S. ; Netto, J.F. ; Francischetti, E.A.</creator><creatorcontrib>Sanjuliani, A.F. ; Barroso, S.G. ; Fagundes, V.G.A. ; Rodrigues, M.L.G. ; Moulin, C.S. ; Netto, J.F. ; Francischetti, E.A.</creatorcontrib><description>The present study has been conducted to evaluate the chronic effects (7 months) of Moxonidine (M) and Amlodipine (A) on lipid profile and urinary sodium excretion in patients with Metabolic Syndrome. Twenty seven obese hipertensive subjects (BMI = 33 ± 1.0, MBP = 124.6 ± 1.6 mmHg, 4 males, 23 females, age 49.3 ± 1.5 yrs) were randomly assigned to receive M [(n = 17), 49.3 ± 1.9 yrs] or A [(n = 10), 48.3 ± 2.4 yrs]. Both A and M caused significant reduction in systolic, diastolic and mean blood pressure (MBP), although no significant difference was observed between the two groups [MBP: M-122.8 ± 1.5 vs 111.2 ± 3.6 mmHg (p = 0.003), A-127.1 ± 2.6 vs 106.0 ± 2.4 (p = 0.0001)]. In conditions of adequate control of sodium and calories intake, the urinary excretion of sodium/creatinine in 12h (NaU) decreased in both groups during blood pressure reduction, but significantly less (p = 0.03) in the M group (21.65 ± 3.992 vs 19.22 ± 2.26 mmol/mmol) when compared to the A group (16.95 ± 2.77 vs 10.92 ± 2.77 mmol/mmol). We observed a significant diminution of energy intake (1987 ± 60, vs 1784 ± 119 calories, p &lt; 0.05), as well as on the waist circumference in the M group (104.4 cm vs 103 cm, p &lt; 0.04), but not in the A group (2229 ± 244 vs 1923 ± 298 calories, p = 0.19 and 100.4 vs 101 cm, p = 0.78). There was a 12% reduction of serum triglycerides concentration with M. Both drugs showed no significant effects on plasma glucose, HDL-C and LDL-C. The administration of M, when compared to A, to obese hypertensive patients reduced the intake of calories, waist circumference and serum triglycerides. Besides having the same antihypertensive efficacy, Moxonidine retained less sodium than Amlodipine.</description><identifier>ISSN: 0895-7061</identifier><identifier>EISSN: 1941-7225</identifier><identifier>DOI: 10.1016/S0895-7061(00)00620-8</identifier><identifier>CODEN: AJHYE6</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>caloric intake ; obesity ; Sodium excretion</subject><ispartof>American journal of hypertension, 2000-04, Vol.13 (S2), p.144A-144A</ispartof><rights>Copyright Nature Publishing Group Apr 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Sanjuliani, A.F.</creatorcontrib><creatorcontrib>Barroso, S.G.</creatorcontrib><creatorcontrib>Fagundes, V.G.A.</creatorcontrib><creatorcontrib>Rodrigues, M.L.G.</creatorcontrib><creatorcontrib>Moulin, C.S.</creatorcontrib><creatorcontrib>Netto, J.F.</creatorcontrib><creatorcontrib>Francischetti, E.A.</creatorcontrib><title>A087: Moxonidine and amlodipine effects on lipid profile, urinary sodium excretion and caloric intake in obese hypertensive patients</title><title>American journal of hypertension</title><addtitle>AJH</addtitle><description>The present study has been conducted to evaluate the chronic effects (7 months) of Moxonidine (M) and Amlodipine (A) on lipid profile and urinary sodium excretion in patients with Metabolic Syndrome. Twenty seven obese hipertensive subjects (BMI = 33 ± 1.0, MBP = 124.6 ± 1.6 mmHg, 4 males, 23 females, age 49.3 ± 1.5 yrs) were randomly assigned to receive M [(n = 17), 49.3 ± 1.9 yrs] or A [(n = 10), 48.3 ± 2.4 yrs]. Both A and M caused significant reduction in systolic, diastolic and mean blood pressure (MBP), although no significant difference was observed between the two groups [MBP: M-122.8 ± 1.5 vs 111.2 ± 3.6 mmHg (p = 0.003), A-127.1 ± 2.6 vs 106.0 ± 2.4 (p = 0.0001)]. In conditions of adequate control of sodium and calories intake, the urinary excretion of sodium/creatinine in 12h (NaU) decreased in both groups during blood pressure reduction, but significantly less (p = 0.03) in the M group (21.65 ± 3.992 vs 19.22 ± 2.26 mmol/mmol) when compared to the A group (16.95 ± 2.77 vs 10.92 ± 2.77 mmol/mmol). We observed a significant diminution of energy intake (1987 ± 60, vs 1784 ± 119 calories, p &lt; 0.05), as well as on the waist circumference in the M group (104.4 cm vs 103 cm, p &lt; 0.04), but not in the A group (2229 ± 244 vs 1923 ± 298 calories, p = 0.19 and 100.4 vs 101 cm, p = 0.78). There was a 12% reduction of serum triglycerides concentration with M. Both drugs showed no significant effects on plasma glucose, HDL-C and LDL-C. The administration of M, when compared to A, to obese hypertensive patients reduced the intake of calories, waist circumference and serum triglycerides. Besides having the same antihypertensive efficacy, Moxonidine retained less sodium than Amlodipine.</description><subject>caloric intake</subject><subject>obesity</subject><subject>Sodium excretion</subject><issn>0895-7061</issn><issn>1941-7225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNo9j01LxDAYhIMouH78BCHgRcFq3qT5qDcRXYV1hVVQvJRs-xaj3bQmWdm9-8OtKJ6GGR5mGEIOgJ0CA3X2wEwhM80UHDF2zJjiLDMbZARFDpnmXG6S0T-yTXZifGOM5UrBiHxdMKPP6V236ryrnUdqfU3tou1q1_9YbBqsUqSdp-2Q1LQPXeNaPKHL4LwNaxoHdLmguKoCJjdwPw2VbbvgKup8su84CO3mGJG-rnsMCX10n0h7mxz6FPfIVmPbiPt_ukser68eL2-yyf349vJikjmlZMaF4Y3QKldSaAbCNraGCszcSKVyDboBIbG2IItCiUblHCrBhK65mBteaLFLDn9rhwsfS4ypfOuWwQ-LJTBhIAcj5UBlv5SLCVdlH9xieFna8F4qLbQsb55fyqnmk9l49lROxTfP7XJm</recordid><startdate>200004</startdate><enddate>200004</enddate><creator>Sanjuliani, A.F.</creator><creator>Barroso, S.G.</creator><creator>Fagundes, V.G.A.</creator><creator>Rodrigues, M.L.G.</creator><creator>Moulin, C.S.</creator><creator>Netto, J.F.</creator><creator>Francischetti, E.A.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200004</creationdate><title>A087: Moxonidine and amlodipine effects on lipid profile, urinary sodium excretion and caloric intake in obese hypertensive patients</title><author>Sanjuliani, A.F. ; Barroso, S.G. ; Fagundes, V.G.A. ; Rodrigues, M.L.G. ; Moulin, C.S. ; Netto, J.F. ; Francischetti, E.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i665-2382f37646537013afad1c18b85664717f135eda159963f6421c3037d23b82973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>caloric intake</topic><topic>obesity</topic><topic>Sodium excretion</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanjuliani, A.F.</creatorcontrib><creatorcontrib>Barroso, S.G.</creatorcontrib><creatorcontrib>Fagundes, V.G.A.</creatorcontrib><creatorcontrib>Rodrigues, M.L.G.</creatorcontrib><creatorcontrib>Moulin, C.S.</creatorcontrib><creatorcontrib>Netto, J.F.</creatorcontrib><creatorcontrib>Francischetti, E.A.</creatorcontrib><collection>Istex</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>American journal of hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanjuliani, A.F.</au><au>Barroso, S.G.</au><au>Fagundes, V.G.A.</au><au>Rodrigues, M.L.G.</au><au>Moulin, C.S.</au><au>Netto, J.F.</au><au>Francischetti, E.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A087: Moxonidine and amlodipine effects on lipid profile, urinary sodium excretion and caloric intake in obese hypertensive patients</atitle><jtitle>American journal of hypertension</jtitle><addtitle>AJH</addtitle><date>2000-04</date><risdate>2000</risdate><volume>13</volume><issue>S2</issue><spage>144A</spage><epage>144A</epage><pages>144A-144A</pages><issn>0895-7061</issn><eissn>1941-7225</eissn><coden>AJHYE6</coden><abstract>The present study has been conducted to evaluate the chronic effects (7 months) of Moxonidine (M) and Amlodipine (A) on lipid profile and urinary sodium excretion in patients with Metabolic Syndrome. Twenty seven obese hipertensive subjects (BMI = 33 ± 1.0, MBP = 124.6 ± 1.6 mmHg, 4 males, 23 females, age 49.3 ± 1.5 yrs) were randomly assigned to receive M [(n = 17), 49.3 ± 1.9 yrs] or A [(n = 10), 48.3 ± 2.4 yrs]. Both A and M caused significant reduction in systolic, diastolic and mean blood pressure (MBP), although no significant difference was observed between the two groups [MBP: M-122.8 ± 1.5 vs 111.2 ± 3.6 mmHg (p = 0.003), A-127.1 ± 2.6 vs 106.0 ± 2.4 (p = 0.0001)]. In conditions of adequate control of sodium and calories intake, the urinary excretion of sodium/creatinine in 12h (NaU) decreased in both groups during blood pressure reduction, but significantly less (p = 0.03) in the M group (21.65 ± 3.992 vs 19.22 ± 2.26 mmol/mmol) when compared to the A group (16.95 ± 2.77 vs 10.92 ± 2.77 mmol/mmol). We observed a significant diminution of energy intake (1987 ± 60, vs 1784 ± 119 calories, p &lt; 0.05), as well as on the waist circumference in the M group (104.4 cm vs 103 cm, p &lt; 0.04), but not in the A group (2229 ± 244 vs 1923 ± 298 calories, p = 0.19 and 100.4 vs 101 cm, p = 0.78). There was a 12% reduction of serum triglycerides concentration with M. Both drugs showed no significant effects on plasma glucose, HDL-C and LDL-C. The administration of M, when compared to A, to obese hypertensive patients reduced the intake of calories, waist circumference and serum triglycerides. Besides having the same antihypertensive efficacy, Moxonidine retained less sodium than Amlodipine.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><doi>10.1016/S0895-7061(00)00620-8</doi></addata></record>
fulltext fulltext
identifier ISSN: 0895-7061
ispartof American journal of hypertension, 2000-04, Vol.13 (S2), p.144A-144A
issn 0895-7061
1941-7225
language eng
recordid cdi_proquest_journals_1038141855
source Oxford Journals Online
subjects caloric intake
obesity
Sodium excretion
title A087: Moxonidine and amlodipine effects on lipid profile, urinary sodium excretion and caloric intake in obese hypertensive patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T07%3A13%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_istex&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A087:%20Moxonidine%20and%20amlodipine%20effects%20on%20lipid%20profile,%20urinary%20sodium%20excretion%20and%20caloric%20intake%20in%20obese%20hypertensive%20patients&rft.jtitle=American%20journal%20of%20hypertension&rft.au=Sanjuliani,%20A.F.&rft.date=2000-04&rft.volume=13&rft.issue=S2&rft.spage=144A&rft.epage=144A&rft.pages=144A-144A&rft.issn=0895-7061&rft.eissn=1941-7225&rft.coden=AJHYE6&rft_id=info:doi/10.1016/S0895-7061(00)00620-8&rft_dat=%3Cproquest_istex%3E2753710621%3C/proquest_istex%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-i665-2382f37646537013afad1c18b85664717f135eda159963f6421c3037d23b82973%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1038141855&rft_id=info:pmid/&rfr_iscdi=true